A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

175

Participants

Timeline

Start Date

March 31, 2002

Primary Completion Date

April 30, 2004

Study Completion Date

April 30, 2004

Conditions
Crohn's DiseaseColitisIntestinal DiseaseGastrointestinal DiseaseDigestive System Disease
Interventions
DRUG

anti-Interferon-gamma monoclonal antibody

Trial Locations (19)

15261

University Pittsburgh Medical Center, Division of Gastroenterology, Hepatology and Nutrition, Inflammatory Bowel Disease Center, Pittsburgh

22908

University of Virginia Health System, Charlottesville

28211

Carolina Digestion Health Associates, Charlottesville

30342

Atlanta Gastroenterology Associates, Atlanta

32608

Gainesville VA Medical Center, Gainesville

33407

Waterside Clinical Research Services, Inc., West Palm Beach

40536

University of Kentucky Medical Center, Division of Digestive Disease & Nutrition, Lexington

44195

The Cleveland Clinic Foundation, Cleveland

45219

Consultants for Clinical Research, Cincinnati

68503

Gastroenterology Specialities P.C., Lincoln

77090

Houston Medical Research Associates, Houston

92801

Advanced Clinical Research Institute, Anaheim

92868

Doctor's Office, Orange

60637-1426

Doctor's Office, Chicago

02114

Massachusetts General Hospital, Gastrointestinal Unit, Boston

V5Z 1M9

Vancouver General Hospital, Dept. of Medicine, Vancouver

R3A 1R9

Health Science Centre, Winnipeg

B3H 1V8

Queen Elizabeth II Health Science Center, McKenzie Building, Pathology, Halifax

N6A 5A5

London Health Science Center, University Campus, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Facet Biotech

INDUSTRY

NCT00072943 - A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease | Biotech Hunter | Biotech Hunter